A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.

Cornell, Robert F; Bishop, Michael R; Kumar, Shaji; Giralt, Sergio A; Nooka, Ajay K; Larson, Sarah M; Locke, Frederick L; Raje, Noopur S; Lei, Lei; Dong, Jinghui; Le Gall, John B; Rossi, John M; Orlowski, Robert Z

Cornell, Robert F; Bishop, Michael R; Kumar, Shaji; Giralt, Sergio A; Nooka, Ajay K; Larson, Sarah M; Locke, Frederick L; Raje, Noopur S; Lei, Lei; Dong, Jinghui; Le Gall, John B; Rossi, John M; Orlowski, Robert Z.

Afiliação

Cornell RF; Vanderbilt University Medical Center Nashville, TN, USA.
Bishop MR; The University of Chicago Medicine Chicago, IL, USA.
Kumar S; Mayo Clinic Rochester, MN, USA.
Giralt SA; Memorial Sloan Kettering Cancer Center NY, USA.
Nooka AK; Winship Cancer Institute, Emory University School of Medicine Atlanta, GA, USA.
Larson SM; UCLA Medical Center Santa Monica, CA, USA.
Locke FL; Moffitt Cancer Center Tampa, FL, USA.
Raje NS; Massachussetts General Hospital Cancer Center Boston, MA, USA.
Lei L; Kite, A Gilead Company Santa Monica, CA, USA.
Dong J; Kite, A Gilead Company Santa Monica, CA, USA.
Le Gall JB; Kite, A Gilead Company Santa Monica, CA, USA.
Rossi JM; Kite, A Gilead Company Santa Monica, CA, USA.
Orlowski RZ; The University of Texas MD Anderson Cancer Center Houston, TX, USA.

Am J Cancer Res ; 11(6): 3285-3293, 2021.

Article em En | MEDLINE | ID: mdl-34249462

Palavras-chave

B-cell maturation antigen; Chimeric antigen receptor T cell; relapsed/refractory multiple myeloma

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Am J Cancer Res Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google